686 related articles for article (PubMed ID: 33921886)
1. SARS-CoV-2 M
Citarella A; Scala A; Piperno A; Micale N
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
[TBL] [Abstract][Full Text] [Related]
2. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
3. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
[TBL] [Abstract][Full Text] [Related]
4. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
[TBL] [Abstract][Full Text] [Related]
5. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
6. Potential SARS-CoV-2 protease M
Kouznetsova VL; Huang DZ; Tsigelny IF
Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
8. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2.
Yassine R; Makrem M; Farhat F
Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259
[TBL] [Abstract][Full Text] [Related]
9. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
Yuda GPWC; Hanif N; Hermawan A
Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
[TBL] [Abstract][Full Text] [Related]
10. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M
Sultan A; Ali R; Ishrat R; Ali S
J Biomol Struct Dyn; 2022; 40(23):12848-12862. PubMed ID: 34569411
[TBL] [Abstract][Full Text] [Related]
12. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704
[TBL] [Abstract][Full Text] [Related]
13. Discovery of SARS-CoV-2 3CL
Wang Y; Xu B; Ma S; Wang H; Shang L; Zhu C; Ye S
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216507
[TBL] [Abstract][Full Text] [Related]
14. The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL
Eberle RJ; Olivier DS; Amaral MS; Gering I; Willbold D; Arni RK; Coronado MA
Viruses; 2021 May; 13(5):. PubMed ID: 34068686
[TBL] [Abstract][Full Text] [Related]
15. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
[TBL] [Abstract][Full Text] [Related]
16. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.
Diniz LRL; Perez-Castillo Y; Elshabrawy HA; Filho CDSMB; de Sousa DP
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33430299
[TBL] [Abstract][Full Text] [Related]
17. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.
Liang J; Karagiannis C; Pitsillou E; Darmawan KK; Ng K; Hung A; Karagiannis TC
Comput Biol Chem; 2020 Dec; 89():107372. PubMed ID: 32911432
[TBL] [Abstract][Full Text] [Related]
18. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
19. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
20. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.
Alhadrami HA; Sayed AM; Sharif AM; Azhar EI; Rateb ME
Molecules; 2021 May; 26(9):. PubMed ID: 34062737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]